NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.
The Board of Directors of Nanologica AB (publ) ("Nanologica" or the Company") announced on 23 August 2022 that the Board of Directors has resolved to carry out a rights issue of shares corresponding to approximately MSEK 94 (the "Rights Issue"). The Board of Directors' resolution on the Rights Issue was approved at an Extraordinary General Meeting on September 15, 2022. A prospectus, prepared in connection with the Rights Issue, has today, September 20, 2022, been approved and registered by the Swedish Financial Supervisory Authority and is available on Nanologica's website www.nanologica.com.
The purpose of the Rights Issue is to finance intensified efforts and investments in the preparative chromatography business area in order to strengthen the Company’s competitiveness and take advantage of the favorable market conditions.
The prospectus has been prepared in connection with the Rights Issue and has today, 20 September 2022, been approved and registered with the Swedish Financial Supervisory Authority. The prospectus, which contains complete terms and conditions, is available on the Company's website www.nanologica.com and on the Swedish Financial Supervisory Authority's website www.fi.se. Application forms will be available on the Company's and Aktieinvest's respective websites. In connection with the start of the subscription period, a summary folder will be sent by mail to Nanologica's directly registered shareholders. The summary folder is also available on the Company's website www.nanologica.com.
Summary of the Rights Issue
- One (1) existing share entitles to one (1) subscription right and three (3) subscription rights entitle the holder to subscribe for one (1) new share.
- The subscription price is set at SEK 10.
- Trade with subscription rights will take place between September 21 to 30.
- The subscription period will run from September 21, 2022 to October 5, 2022.
- The Rights Issue comprises a maximum of 9,388,608 new shares. Upon full subscription of the Rights Issue, Nanologica will receive approximately MSEK 94 before transaction costs, which are estimated to MSEK 3.5.
- The Rights Issue is covered to approximately 47.6 percent by subscription commitments and is guaranteed up to 85 percent.
For more detailed information about the Rights Issue, please refer to the published prospectus.
On September 27, 2022, at 12.00 CET, Nanologica invites to a presentation and Q&A session with the Company’s CEO Andreas Bhagwani at Infront Direkt Studios, Kungsgatan 33, 115 56 Stockholm. Registration is made to firstname.lastname@example.org. The presentation will also be broadcast live via link.
Zonda Partners and Advokatfirman Lindahl are acting as financial and legal advisors to Nanologica in connection with the Rights Issue. Aktieinvest acts as issuing agent.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: email@example.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung, to provide new treatment options for patients with lung diseases. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed for trade on Nasdaq Stockholm Main Market since 29 mars, 2022. For further information, please visit www.nanologica.com.
The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and comply with such legal restrictions.The recipient of this press release is responsible for using this press release and the information contained herein in accordance with applicable rules in the respective jurisdiction.This press release does not constitute an offer to sell or a solicitation of an offer to acquire or subscribe for securities issued by the Company in any jurisdiction in which such offer or solicitation would be unlawful. In a member state of the European Economic Area (“EEA”), securities referred to in this press release may only be offered in accordance with the applicable exemptions in Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”).
This press release does not constitute an offer or invitation to acquire or subscribe for securities of the United States.The securities referred to herein may not be sold in the United States absent registration, or without application of an exemption from registration, under the U.S. Securities Act, as amended, of 1933 (the “Securities Act”), and may not be offered or sold in the United States without being registered, subject to: of an exemption from, or in a transaction that is not subject to, the registration requirements of the Securities Act.There is no intention to register any securities referred to herein in the United States or to disclose a public offering of such securities in the United States. The information in this press release may not be published, published, copied, reproduced or distributed, directly or indirectly, in whole or partially, in or into the United States, Australia, Canada, Japan, Hong Kong, New Zealand, Singapore, Switzerland, South Africa or any other jurisdiction in which such release, publication or distribution of this information would be in violation of applicable regulations or where such an action is subject to legal restrictions or would require additional registration or other measures than what follows from Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities laws.
A prospectus relating to the Rights Issue described in this press release will be announced by the Company on or about 20 September 2022. The prospectus will be approved and is registered by the Swedish Financial Supervisory Authority, which is the competent authority under the Prospectus Regulation and be published by the Company and be made available on the Company’s website www.nanologica.com after such approval obtained. The Swedish Financial Supervisory Authority’s upcoming approval of the prospectus shall not be perceived as some kind of support for the Company or for the quality of the securities referred to in Prospectus. This press release is not a prospectus within the meaning of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. Possibly investment decisions should, in order for an investor to fully understand the potential risks and benefits associated with the decision to participate in the Rights Issue, made solely on the basis of the information contained in the prospectus. Thus, an investor is advised to read the entire prospectus. This press release constitutes marketing within the meaning of Article 2(k) of the Prospectus Regulation. Nanologica has not accepted any offer to the public of shares or rights in any other Member State of the EEA other than Sweden. This press release does not identify or purport to identify risks (direct or indirect) that may be associated with an investment in shares. Investment decisions to acquire or subscribe for shares in the Rights Issue may only be made based on publicly available information.
To the extent this press release contains forward-looking statements, statements are not facts and are characterized by words such as “should”, “expect”, “believe”, “estimate”, “intend”, “intends”, “assumes” and similar expressions. Such statements express Nanologica’s intentions, opinions or current expectations or assumptions. Such forward-looking statements are based on current plans, estimates and forecasts that Nanologica has made to the best of its ability but which Nanologica does not claim will be accurate in the future. Forward-looking statements are compounded with risks and uncertainties that are difficult to predict and generally cannot be influenced by Nanologica. It should be kept in mind that actual events or outcomes may differ materially from those covered of, or expressed in, such forward-looking statements.